Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C.

Nat Neurosci. 2009 Jul;12(7):826-8. doi: 10.1038/nn.2349. Epub 2009 Jun 7.

2.

Mouse models for LRRK2 Parkinson's disease.

Xu Q, Shenoy S, Li C.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S186-9. doi: 10.1016/S1353-8020(11)70058-X. Review.

PMID:
22166430
3.

Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Lee BD, Dawson VL, Dawson TM.

Trends Pharmacol Sci. 2012 Jul;33(7):365-73. doi: 10.1016/j.tips.2012.04.001. Epub 2012 May 9. Review.

4.

A BACwards glance at neurodegeneration: molecular insights into disease from LRRK2, SNCA and MAPT BAC-transgenic mice.

Johnson SJ, Wade-Martins R.

Biochem Soc Trans. 2011 Aug;39(4):862-7. doi: 10.1042/BST0390862. Review.

PMID:
21787314
5.

Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.

Sloan M, Alegre-Abarrategui J, Wade-Martins R.

Biochem Soc Trans. 2012 Oct;40(5):1080-5. Review.

PMID:
22988869
6.

Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.

Yue Z, Lachenmayer ML.

Mov Disord. 2011 Jul;26(8):1386-97. doi: 10.1002/mds.23737. Epub 2011 Apr 29. Review.

7.

LRRK2 Parkinson's disease: from animal models to cellular mechanisms.

Lin CH, Tsai PI, Wu RM, Chien CT.

Rev Neurosci. 2011;22(4):411-8. doi: 10.1515/RNS.2011.036. Epub 2011 Jun 17. Review.

PMID:
21679126
8.

A trojan horse for Parkinson's disease.

Hu Y, Tong Y.

Sci Signal. 2010 Apr 6;3(116):pe13. doi: 10.1126/scisignal.3116pe13. Review.

PMID:
20371768
9.

Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.

Yue Z.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S180-2. doi: 10.1016/S1353-8020(11)70056-6. Review.

10.

Mutations in LRRK2 as a cause of Parkinson's disease.

Giasson BI, Van Deerlin VM.

Neurosignals. 2008;16(1):99-105. Epub 2007 Dec 5. Review.

PMID:
18097165
11.

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):221-9. Review.

PMID:
17017533
12.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
13.

[Advance of the study on LRRK2 gene in Parkinson's disease].

Zhang Y, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):657-9. Review. Chinese.

PMID:
19065525
14.

The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.

Ekstrand MI, Galter D.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S185-8. doi: 10.1016/S1353-8020(09)70811-9. Review.

PMID:
20082987
15.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
16.

The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2.

Bonifati V.

Curr Neurol Neurosci Rep. 2006 Sep;6(5):355-7. Review. No abstract available.

PMID:
16928343
17.

LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis.

Volta M, Melrose H.

Biochem Soc Trans. 2017 Feb 8;45(1):113-122. doi: 10.1042/BST20160238. Review.

PMID:
28202664
18.

Genetic mouse models of Parkinson's disease The state of the art.

Magen I, Chesselet MF.

Prog Brain Res. 2010;184:53-87. doi: 10.1016/S0079-6123(10)84004-X. Review.

PMID:
20887870
19.

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Taymans JM, Greggio E.

Curr Neuropharmacol. 2016;14(3):214-25. Review.

20.

Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Bezard E, Yue Z, Kirik D, Spillantini MG.

Mov Disord. 2013 Jan;28(1):61-70. doi: 10.1002/mds.25108. Epub 2012 Jul 2. Review.

Supplemental Content

Support Center